Page 339 - Vitamin D and Cancer

326 R. Vieth

47. Hsu JY, Feldman D, McNeal JE, Peehl DM (2001) Reduced 1alpha-hydroxylase activity in
human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin
D3-induced growth inhibition. Cancer Res 61(7):2852–2856
48. Harris SS, Dawson-Hughes B (1998) Seasonal changes in plasma 25-hydroxyvitamin D con-
centrations of young American black and white women. Am J Clin Nutr 67(6):1232–1236
49. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD et al (2007) The
effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin
D sufficiency. Am J Clin Nutr 86(4):959–964
50. Kimlin MG (2008) Geographic location and vitamin D synthesis. Mol Aspects Med
29(6):453–461
51. Tan J, Dwivedi PP, Anderson P, Nutchey BK, O’Loughlin P, Morris HA et al (2007)
Antineoplastic agents target the 25-hydroxyvitamin D3 24-hydroxylase messenger RNA for
degradation: implications in anticancer activity. Mol Cancer Ther 6(12 Pt 1):3131–3138
52. Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality:
a review (United States). Cancer Causes Control 16(2):83–95
53. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium
in combination with vitamin D supplementation to prevent fractures and bone loss in people
aged 50 years and older: a meta-analysis. Lancet 370(9588):657–666
54. Bischoff-Ferrari HA (2007) How to select the doses of vitamin D in the management of
osteoporosis. Osteoporos Int 18(4):401–407
55. Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.
Am J Clin Nutr 69(5):842–856
56. Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol)
supplementation on fractures and mortality in men and women living in the community:
randomised double blind controlled trial. BMJ 326:469–475
57. Buxton ILO (2006) Pharmacokinetics and pharmacodynamics: the dynamics of drug absorp-
tion, distribution, action, and elimination. In: Brunton LL (ed) Goodman & Gilman’s the
pharmacological basis of therapeutics, 11th edn. McGraw-Hill, Medical Publishing Division,
New York, pp 1–41
58. Vieth R (2007) Vitamin D toxicity, policy, and science. J Bone Miner Res 22(Suppl
2):V64–V68
59. Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3
in humans. J Clin Endocrinol Metab 89(11):5387–5391
60. Kruk ME, Schwalbe N (2006) The relation between intermittent dosing and adherence:
preliminary insights. Clin Ther 28(12):1989–1995
61. Rossini M, Viapiana O, Gatti D, James G, Girardello S, Adami S (2005) The long term
correction of vitamin D deficiency: comparison between different treatments with vitamin D
in clinical practice. Minerva Med 96(2 Suppl 2):1–7
62. Barreto AM, Schwartz GG, Woodruff R, Cramer SD (2000) 25-Hydroxyvitamin D3, the
prohormone of 1, 25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic
epithelial cells. Cancer Epidemiol Biomarkers Prev 9(3):265–270
63. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS (2006) Vitamin
D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol
Biomarkers Prev 15(9):1688–1695
64. Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC et al (2004) Pancreatic
cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is
inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25(6):1015–1026